



For Wound Care



The Science

In short, based on groundbreaking clinical trial results, transdermal CO, delivery with D'OXYVA® has recorded unmatched, sustained skin perfusion pressure increase in all subjects, indicating powerful increase in the activation of vasodilation, tissue perfusion, cell respiration and metabolism. The Bohr effect is widely known for facilitating oxygen offloading when the red blood cell's hemoglobin exchanges CO, and H,O that in turn thought to signal the body to increase endothelial function, oxygen and blood levels. For a more technical explanation on microcirculation and its effects, please read the references by following the highlighted links on our website.

Promising Non-Invasive Wound Application

Studies have shown extraordinary results for the role of transdermal CO₂ in wound care. Patients and physicians report quicker, more comfortable healing, closure, and overall recovery from trauma and so-called non-healing wounds related to diabetes and cardiovascular complications, and lower instances of infection. Sleeping, eating, mood and pain improves significantly.

The vapor exiting the water capsule is almost imperceptible when sprayed onto the skin and the wound. It is painless, free of any needles, safe and powerful, with no adverse side effects according to past clinical trials with D`OXYVA®.

The D'OXYVA® product is considered an investigational device in the U.S. when used for medical purposes such as wound healing and closure and it has an "investigational device exemption" ("IDE") status because it has been the subject of IRB-approved studies on human subjects identified as a Non-Significant Risk (NSR) device.

- Powerful, Affordable, Convenient
- •Painless, Safe, and Non-Invasive
- •Handheld, Needing Very Little Storage or Counter Space
- Operates Simply With Water
- Each Application is Only 5 Minutes
- •A Stand Alone or Adjunct Solution Incorporated With Existing Services





Wound Healing Case Studies





BEFORE AFTER (25 DAYS)

A 68-year-old insulin-dependent septic diabetic male patient with unbalanced glycaemic status had a forklift truck accident suffering trimalleolar fracture with massive soft tissue contusion, crural decollement, and mixed bacterial infection. Necrotized skin on the heel, medial malleoli, shin's anterior surface. Under treatment at the Semmelweis University Hospital, Hungary (EU), the wounds were not healing after several generally-accepted applications after 2 months and amputation was imminent when D`OXYVA® application started 2x per day, sprayed directly on the wound.







AFTER (6 WEEKS)

Male patient with severe diabetec and cardiovascular complications with extreme neuropathy pain and high blood pressure lower extremity wounds spreading from lower extremeties to upper body and arms. D'OXYVA® application started 2x per day, on the thumb and near the wounds.

LEGAL DISCLAIMER

Copyright © 2015 Circularity Healthcare, LLC. All rights reserved. D'OXYVA and Circularity are trademarks and/or registered trademarks of Circularity Healthcare in the U.S. and other countries. All other trademarks mentioned here belong to their owners. Third party brands, product names, trade names, corporate names and company names mentioned may be trademarks of their respective owners or registered trademarks of other companies and are used for purposes of explanation and to the owner's benefit without implying a violation of copyright law. Circularity's D'OXYVA has not been evaluated yet by the U.S. Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, or prevent any disease. The information provided in this catalog is for educational purposes and is not intended to replace medical advice. Ask your physician or therapist about using D'OXYVA. Results may vary by individual.



